Previous 10 | Next 10 |
BOSTON, Feb. 22, 2022 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company committed to transforming the care of people living with rare genetic diseases of obesity, today announced that it will host a live conference call and webcast...
Rhythm Pharmaceuticals (RYTM +12.1%) has recorded the biggest intraday gain since November 2020 after Ladenburg Thalmann upgraded the commercial-stage biopharmaceutical company to Buy from Neutral. The firm highlighted the prospects of Imcivree, an FDA-approved therapy marketed by the company...
Gainers: Aridis Pharmaceuticals ARDS +12%. Rhythm Pharmaceuticals RYTM +12%. Outset Medical (NASDAQ:OM) +10%. Masimo (NASDAQ:MASI) +8%. Vivos Therapeutics (NASDAQ:VVOS) +7%. Losers: 10x Genomics (NASDAQ:TXG) -16%. iSpecimen ISPC -10%. Poseida ...
Marin Software (NASDAQ:MRIN) +25% on TikTok integration in platform. DoorDash (NYSE:DASH) +24% on Q4 results. Global-e Online (NASDAQ:GLBE) +15% on Q4 results. TriNet (NYSE:TNET) +9% commences a modified dutch auction tender offer to repurchase up to $300M o...
-- Patients with BBS achieved deepened and sustained weight loss at 24 months on setmelanotide therapy -- -- Company to provide update on U.S. BBS commercial readiness during virtual event today at 4 p.m. ET -- BOSTON, Feb. 16, 2022 (GLOBE NEWSWIRE) -- Rhythm Pharmaceutica...
-- Key opinion leaders and patient caregiver to discuss patient experience -- -- Company to provide update on U.S. BBS commercial readiness during event for investors and analysts -- -- Prescription Drug User Fee Act (PDUFA) goal date for setmelanotide for patients w...
-- DAYBREAK is the most comprehensive Phase 2 trial ever initiated in rare genetic diseases of obesity -- -- DAYBREAK is evaluating setmelanotide in patients with severe obesity and hyperphagia caused by variants in one of 31 pre-identified genes -- -- First patient also dosed...
Rhythm Pharmaceuticals (NASDAQ:RYTM) announces an exclusive licensing agreement with and China-based RareStone LTD, for the development and commercialization of Imcivree (setmelanotide) in China, including mainland China, Hong Kong and Macau. According to the terms of the agreement, RareStone...
-- RareStone to seek marketing authorization for IMCIVREE to treat obesity due to biallelic POMC, PCSK1 and LEPR deficiencies and Bardet-Biedl and Alström syndromes in mainland China, Hong Kong and Macau -- -- Rhythm to receive $12 million upfront in cash and equity, up to $63....
Rhythm Pharmaceuticals (NASDAQ:RYTM) has added ~5.4% in the pre-market after announcing that the FDA accepted the company’s supplemental New Drug Application ((sNDA)) for IMCIVREE (setmelanotide) for Bardet-Biedl syndrome (BBS) or Alström syndrome. The regulator has...
News, Short Squeeze, Breakout and More Instantly...
Rhythm Pharmaceuticals Inc. Company Name:
RYTM Stock Symbol:
NASDAQ Market:
Rhythm Pharmaceuticals Inc. Website:
-- LB54640 has shown targeted effect on MC4R without hyperpigmentation -- BOSTON, July 23, 2024 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families living with r...
BOSTON, July 23, 2024 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families living with rare neuroendocrine diseases, today announced that it will host a live conference call a...
BOSTON, July 08, 2024 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families living with rare neuroendocrine diseases, today announced the appointment of Alastair “Al...